Steatohepatitis promotes the progression of psoriasis in patients with NASH, and obesity exaggerates the severity of psoriasiform dermatitis caused by the Toll-like receptor 7 (TLR-7) agonist imiquimod (IMQ) by promoting IL-17A and IL-22 secretion and IL-1β overexpression in HFD-fed mice [33,45,46]. Here, IL22 is linked to obesity disorder.